Cyclazosin
Cyclazosin is an α1D-adrenergic receptor antagonist and a partial agonist of CXCR4/ACKR3. The pKi values of Cyclazosin for cloned human α1D, α1B and α1A adrenergic receptors are 9.28, 9.23 and 8.18, respectively. Cyclazosin induces β-arrestin recruitment in CXCR4 and ACKR3 with EC50 values of 16 μM and 10 μM, respectively, stimulates ERK1/2 phosphorylation, and induces receptor internalization. Cyclazosin potently inhibits CXCL12-induced chemotaxis of primary human aortic vascular smooth muscle cells. Cyclazosin alters MDMA-induced thermoregulatory responses in mice, converting monophasic hyperthermia to a biphasic pattern without affecting resting core body temperature. Cyclazosin can be used for diseases related to tumor metastasis, MDMA-induced hyperthermia and vasoconstriction.
For research use only. We do not sell to patients.
- CAS No.: 139953-73-4
- Formula: C23H27N5O4
- Molecular Weight:437.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Adrenergic Receptor Isoforms
More
Biological Activity
Description
|
Alpha-1A adrenergic receptor 8.18 (pKi) |
Alpha-1A adrenergic receptor 9.23 (pKi) |
Alpha-1D adrenergic receptor 9.28 (pKi) |
CXCR3 10 μM (EC50) |
CXCR4 16 μM (IC50) |
ERK1 |
ERK2 |
In Vitro
Cyclazosin (30 min) exhibits 10- to 15-fold higher affinity for cloned α1b-adrenergic receptors (pKi = 9.23) and cloned α1d-adrenergic receptors (pKi = 9.28) expressed in COS-7 cells than for cloned α1a-adrenergic receptors (pKi = 8.18), and fails to distinguish between the α1b and α1d subtypes[1].
Cyclazosin (2h) binds with high affinity to human α1A, α1B, and α1D adrenergic receptors expressed in CHO-K1 cells. It shows 9.5-fold selectivity for the α1D subtype over the α1A subtype, and exhibits biphasic binding characteristics at the α1D adrenergic receptor[5].
Cyclazosin (0.01-100 μM; 2 h, followed by overnight incubation) acts as a partial agonist of CXCR4 and ACKR3, inducing β-arrestin recruitment (with EC50 values of 16 μM and 10 μM, respectively); its CXCR4 activity is inhibited by AMD3100 (HY-10046), while its ACKR3 activity remains unaffected[2].
Cyclazosin (100 μM; 5-45 min) induces ERK1/2 phosphorylation in HEK293 cells overexpressing either ACKR3 or CXCR4. In ACKR3-expressing cells, its phosphorylation time course is consistent with that of CXCL12 and is not affected by AMD3100, whereas in CXCR4-expressing cells, it exhibits a delayed and persistent pattern, and this effect is inhibited by AMD3100[2].
Cyclazosin (200 μM) binds directly to CXCR4 and ACKR3 in membrane preparations, and induces detectable structural rearrangements in both receptors as detected by 1H-13C HSQC NMR[2].
Cyclazosin (100 μM; 15-30 min) induces time-dependent internalization of endogenous CXCR4 and ACKR3 in primary human aortic vascular smooth muscle cells, and their surface expression levels decrease to approximately 35% of the baseline level after 30 minutes of treatment with 100 μM Cyclazosin[2].
Cyclazosin (10-13-10-7 M; 3 h) potently inhibits CXCL12-induced chemotaxis of primary human aortic vascular smooth muscle cells, with an IC50 of 11.6 pM, and shows no cytotoxicity at concentrations up to 1 mM[2].
Cyclazosin (0.1-10 nM; 1 hour) acts as a high-affinity antagonist of α1B-adrenergic receptor-mediated adrenaline-induced contraction of human umbilical vein rings, with a pA2 value of 9.75[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HEK293 cells transfected with HA-CXCR4 and HA-ACKR3 plasmid
-
Concentration:100 μM; 10 μM AMD3100 (pre-incubation)
-
Incubation Time:0, 5, 15, 30 and 45 min; 20 min (after 15 min AMD3100 pre-incubation)
-
Result:In CXCR4-overexpressing HEK293 cells, cyclazosin induced a 3-fold increase in ERK1/2 phosphorylation with a delayed and prolonged time course compared to CXCL12 (peak at 15–30 min vs 5 min), and this effect was significantly reduced by AMD3100.
In ACKR3-overexpressing cells, cyclazosin induced ERK1/2 phosphorylation with a time course identical to that of CXCL12, albeit with a weaker magnitude than CXCL12 or prazosin, and AMD3100 had no effect on this response.
-
Cell Line:Primary human aortic vascular smooth muscle cells (hVSMCs)
-
Concentration:10-13, 10-12, 10-11, 10-10, 10-9, 10-8 and 10-7 M
-
Incubation Time:3 h
-
Result:Did not induce chemotaxis on its own. Potently and fully inhibited CXCL12-induced chemotaxis in a dose-dependent manner with an IC₅₀ of 11.6 pM. No cytotoxicity was observed at concentrations up to 1 mM in parallel Trypan Blue exclusion assays.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Conscious male C57 wild-type mice (22-35 g) implanted with radiotelemetric devices in the abdominal cavity under ether anesthesia; allowed 14 days recovery before experiments[4]
-
Dosage:1.0 mg/kg
-
Administration:s.c.; single dose
-
Result:Did not significantly alter resting core body temperature compared to vehicle-treated mice.
Converted MDMA's typical monophasic hyperthermic response to a biphasic response, with an initial significant decrease in core temperature reaching a minimum 40 minutes after MDMA administration, followed by a temperature rise to levels similar to MDMA-only treated mice.
Failed to significantly reduce the maximum hyperthermia induced by MDMA compared to vehicle-pretreated controls.
Chemical Information
-
CAS No. 139953-73-4
-
Molecular Weight 437.49
-
Formula C23H27N5O4
-
SMILES
O=C(C1=CC=CO1)N2[C@]3([H])[C@](CCCC3)([H])N(C4=NC5=C(C=C(C(OC)=C5)OC)C(N)=N4)CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Chemotaxis Gradient Chamber Assay 1
The chemotaxis gradient chamber assay is based on the principle of observing directional cell migration in response to a stable, linear or quasi-linear concentration gradient of a chemoattractant formed between two fluid reservoirs separated by a narrow observation chamber. Cells placed within the chamber respond to the gradient by polarized movement toward higher chemoattractant concentrations, allowing quantification of chemotactic behavior in real time under microscopy. The classic Zigmond chamber design enables simultaneous visualization of gradient formation and individual cell trajectories, making it suitable for studying leukocyte chemotaxis and other motile cell types in vitro.
-
Under-Agarose Cell Migration Assay
The under-agarose cell migration assay is a classical in vitro chemotaxis method designed to evaluate directed cell movement through a semi-solid agarose matrix toward soluble chemoattractant gradients, enabling visualization and quantification of leukocyte or motile cell migration in a confined 2D-like environment. In this system, cells and chemoattractants are placed in separate wells cut into an agarose gel, allowing diffusion-driven gradient formation that guides directional migration, which is typically assessed by measuring migration distance, cell morphology changes, and accumulation toward the chemoattractant source. This assay has been widely used to study neutrophil and leukocyte chemotaxis as a simple alternative to filter-based migration systems and allows direct microscopic observation of migrating cells under near-physiological confinement conditions.
-
Transwell/Boyden Chamber Migration Assay
The Transwell/Boyden chamber migration assay measures cell movement through a porous membrane separating an upper and lower chamber, usually after a chemoattractant gradient is established by placing cells in the upper chamber and chemoattractant-containing medium in the lower chamber. The readout is generated by quantifying cells that traverse the membrane and appear on the lower membrane surface or in the lower chamber, depending on whether the cell type is adherent or non-adherent. This assay reflects chemotactic or haptotactic migration rather than matrix invasion unless an extracellular-matrix barrier is added to the membrane.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Chemotaxis Gradient Chamber Assay 2
Chemotaxis gradient chamber assays measure directional cell migration in response to a soluble chemical gradient by imaging cells as they move across a defined observation region; the readout is generated from time-lapse cell trajectories, displacement toward the gradient, forward migration index, trajectory plots, rose/polar plots, and statistical tests of non-random directionality. The Dunn chamber is a direct-viewing glass chamber in which cells migrate across a bridge between control and chemoattractant wells, allowing observation of cells in a linear concentration gradient; related direct-viewing formats include the Insall chamber, which supports defined unidirectional gradients and high numerical-aperture microscopy, and the μ-Slide Chemotaxis chamber, which supports long-term live-cell imaging and gradient characterization with fluorescent dye.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
References
[1]. Giardinà D, et al. Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist. Eur J Pharmacol. 1995 Dec 4;287(1):13-6. [Content Brief]
[2]. Gao X, et al. Partial agonist activity of α1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3. PLoS One. 2018 Sep 24;13(9):e0204041. [Content Brief]
[3]. Bexis S, et al. Role of alpha1-adrenoceptor subtypes in the effects of methylenedioxy methamphetamine (MDMA) on body temperature in the mouse. British journal of pharmacology. 2008 Feb;153(3):591-7. [Content Brief]
[4]. Alsufyani HA, et al. Both α- and α-adrenoceptor subtypes are involved in contractions of rat spleen. Pharmacological reports : PR. 2021 Feb;73(1):255-260. [Content Brief]
[5]. Proudman RGW, et al. The affinity and selectivity of α-adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D-adrenoceptors. Pharmacology research & perspectives. 2020 Aug;8(4):e00602. [Content Brief]
[6]. Errasti AE, et al. Human umbilical vein vasoconstriction induced by epinephrine acting on alpha1B-adrenoceptor subtype. American journal of obstetrics and gynecology. 2003 Nov;189(5):1472-80. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)